Open AccessGenomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine
Author(s) -
Sebastián Mondaca,
Pedram Razavi,
ChongRui Xu,
Michael Offin,
Michael L. Myers,
Maurizio Scaltriti,
Jaclyn F. Hechtman,
Mikaela Bradley,
Eileen Mary O'Reilly,
Michael F. Berger,
David B. Solit,
Bob T. Li,
Ghassan K. AbouAlfa
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.19.00223
Subject(s) - trastuzumab emtansine , trastuzumab , oncology , medicine , cancer , breast cancer
Biliary tract cancers (BTCs), which include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (EHC), and gallbladder cancer (GBC), have limited treatment options. We sought to comprehensively examine the clinical and molecular characteristics of BTCs with amplification or mutation of ERBB2 .